APRE supply chain intelligence for Aprea Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Aprea Therapeutics, Inc. (APRE) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from APRE graph: Reciprocal relationship from AZN graph: Reciprocal relationship from APRE graph: Reciprocal relationship from AZN grap… |
| CPRX | Catalyst Pharmaceuticals, Inc. | 72% | at the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. In addition, the manufacturer of an investigational dr… |
| CPRX | Catalyst Pharmaceuticals, Inc. | 72% | Reciprocal relationship from CPRX graph: Reciprocal relationship from APRE graph: at the product no longer meets the conditions for qualification or decide that the time period for FDA review or appr… |
| ORANY | ORANY | 72% | l disruption of our development programs, business operations, a breach of sensitive personal information or a loss or corruption of critical data assets including trade secrets or other proprietary … |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from APRE graph: l disruption of our development programs, business operations, a breach of sensitive personal information or a loss … |
| SDGR | Schrödinger, Inc. | 72% | Reciprocal relationship from SDGR graph: g technology. Our ability to remain competitive will largely depend on our ability to continue to improve our computational platform and demonstrate success i… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AZN | AstraZeneca PLC | 72% | gh similar mechanisms of action, including product candidates in clinical development being tested by Artios Pharma Ltd., AstraZeneca Plc, Bayer AG, IMPACT Therapeutics, Inc., and Xeno Therapeutics (… |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from APRE graph: Reciprocal relationship from AZN graph: Reciprocal relationship from APRE graph: gh similar mechanisms of action, incl… |
| ORANY | ORANY | 72% | l disruption of our development programs, business operations, a breach of sensitive personal information or a loss or corruption of critical data assets including trade secrets or other proprietary … |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from APRE graph: l disruption of our development programs, business operations, a breach of sensitive personal information or a loss … |
| SDGR | Schrödinger, Inc. | 72% | Reciprocal relationship from SDGR graph: g technology. Our ability to remain competitive will largely depend on our ability to continue to improve our computational platform and demonstrate success i… |
| ZNTL | Zentalis Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ZNTL graph: ates for preclinical and clinical testing, as well as for commercial manufacture if our product candidates receive marketing approval. We require that our CMO… |
| ARTIOS-PHARMA-LTD-ASTRAZENECA-PLC-BAYER-AG | ARTIOS-PHARMA-LTD-ASTRAZENECA-PLC-BAYER-AG | 62% | gh similar mechanisms of action, including product candidates in clinical development being tested by Artios Pharma Ltd., AstraZeneca Plc, Bayer AG, IMPACT Therapeutics, Inc., and Xeno Therapeutics (… |
| CO-LLC | CO-LLC | 62% | entered into an At the Market Offering Agreement, or the 2024 ATM Agreement, with H.C. Wainright & Co., LLC, or HCW. Pursuant to the 2024 ATM Agreement and the prospectus supplement filed in connecti… |
| IMPACT-THERAPEUTICS-INC | IMPACT-THERAPEUTICS-INC | 62% | gh similar mechanisms of action, including product candidates in clinical development being tested by Artios Pharma Ltd., AstraZeneca Plc, Bayer AG, IMPACT Therapeutics, Inc., and Xeno Therapeutics (… |
| REPARE-THERAPEUTICS-INC | REPARE-THERAPEUTICS-INC | 62% | gh similar mechanisms of action, including product candidates in clinical development being tested by Artios Pharma Ltd., AstraZeneca Plc, Bayer AG, IMPACT Therapeutics, Inc., and Xeno Therapeutics (… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| APRE-DEBT-7805 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| APRE-DEBT-7804 | Warrants outstanding: 91 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| APRE-OWNER-MORGAN-STANLEY | Morgan Stanley | 95% | 13F/ownership overlay lists Morgan Stanley; shares held 77,030; ownership 0.67%; value $70,621; as of 2025-12-31. |
| APRE-OWNER-CITADEL-ADVISORS-LLC | Citadel Advisors Llc | 95% | 13F/ownership overlay lists Citadel Advisors Llc; shares held 51,041; ownership 0.45%; value $46,794; as of 2025-12-31. |
| APRE-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC | Geode Capital Management, LLC | 95% | 13F/ownership overlay lists Geode Capital Management, LLC; shares held 40,950; ownership 0.36%; value $37,542; as of 2025-12-31. |
| APRE-OWNER-AIGH-CAPITAL-MANAGEMENT-LLC | AIGH Capital Management LLC | 95% | 13F/ownership overlay lists AIGH Capital Management LLC; shares held 370,541; ownership 3.24%; value $339,711; as of 2025-12-31. |
| APRE-OWNER-MURCHINSON-LTD | Murchinson Ltd. | 95% | 13F/ownership overlay lists Murchinson Ltd.; shares held 340,139; ownership 2.97%; value $311,839; as of 2025-12-31. |
| APRE-OWNER-SPHERA-FUNDS-MANAGEMENT-LTD | Sphera Funds Management Ltd. | 95% | 13F/ownership overlay lists Sphera Funds Management Ltd.; shares held 270,000; ownership 2.36%; value $247,536; as of 2025-12-31. |
| APRE-OWNER-VANGUARD-GROUP-INC | Vanguard Group Inc | 95% | 13F/ownership overlay lists Vanguard Group Inc; shares held 58,086; ownership 0.51%; value $53,253; as of 2025-12-31. |
| APRE-OWNER-NANTAHALA-CAPITAL-MANAGEMENT-LLC | Nantahala Capital Management, LLC | 95% | 13F/ownership overlay lists Nantahala Capital Management, LLC; shares held 205,760; ownership 1.80%; value $188,640; as of 2025-12-31. |
| APRE-OWNER-JANE-STREET-GROUP-LLC | Jane Street Group, LLC | 95% | 13F/ownership overlay lists Jane Street Group, LLC; shares held 46,621; ownership 0.41%; value $42,742; as of 2025-12-31. |
| APRE-OWNER-DRW-SECURITIES-LLC | DRW Securities, LLC | 95% | 13F/ownership overlay lists DRW Securities, LLC; shares held 120,651; ownership 1.05%; value $110,612; as of 2025-12-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BCAX | Bicara Therapeutics Inc. | 100.00 | 2 | |
| DRTS | Alpha Tau Medical Ltd. | 100.00 | 2 | |
| NVO | Novo Nordisk A/S | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| CPMV | Mosaic ImmunoEngineering, Inc. | 100.00 | 2 | |
| GILD | Gilead Sciences, Inc. | 100.00 | 2 | |
| CCCC | C4 Therapeutics, Inc. | 100.00 | 2 | |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 2 | |
| ORANY | ORANGE | 100.00 | 1 | ['customer', 'supplier'] |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 100.00 | 1 | ['supplier'] |
| SDGR | Schrödinger, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| BMY | Bristol-Myers Squibb Company | 100.00 | 2 | |
| BMYMP | Bristol-Myers Squibb Co | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 1 | ['customer', 'supplier'] |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| IDYA | IDEAYA Biosciences, Inc. | 100.00 | 2 |